New GSMA Report Predicts Chinese IoT Market Will Exceed One Billion Connections by 2020, Underpinned by Licensed Low Power, Wide Area Market
China’s machine-to-machine (M2M) market will reach one billion connections by 2020, with the majority coming from the developing Low Power, Wide Area (LPWA) market, according to a new report released today by GSMA Intelligence and The China Academy of Information and Communications Technology (CAICT). The report, ‘Mobile Operators and Digital Transformation’, highlights that China is currently the world’s largest M2M market with approximately 100 million cellular M2M connections, a figure that is expected to increase to 350 million by 2020. However, an additional 730 million connections will be enabled by LPWA technology, taking the total figure to just over one billion. By 2025, it is expected that 50 per cent of the world’s 28 billion connected devices will be suitable for connection by LPWA networks.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160628005096/en/
New GSMA Report Predicts Chinese IoT Market Will Exceed One Billion Connections by 2020, Underpinned by Licensed Low Power, Wide Area Market (Photo: Business Wire)
“With government support, China has quickly become the world’s largest M2M market, and LPWA will play a fundamental part of its future growth, presenting new opportunities for key industry sectors and for operators to provide connectivity across the country,” said Alex Sinclair, Chief Technology Officer, GSMA. “The GSMA’s Mobile IoT Initiative is working with China’s mobile network operators to deliver commercial LPWA solutions in licensed spectrum to accelerate adoption and transform the development of the Internet of Things in areas such as agriculture, automotive and utilities.”
LPWA networks are designed for M2M applications that have low data rates, require long battery lives and operate unattended for long periods of time, often in remote locations. The GSMA Mobile IoT Initiative has coalesced the industry behind global technology standards in licensed spectrum for the LPWA market, which have now been published by 3GPP. Three complementary technologies – Narrow Band IoT (NB-IoT), EC-GSM-IOT and LTE Machine Type Communication (LTE-MTC) – will cover all LPWA use cases, ensuring customer choice and helping the IoT market to flourish.
Licensed LPWA networks complement and extend conventional wide area networks, which make use of 2G and 4G cellular technologies, as well as local area networks such as WiFi, Bluetooth and Zigbee. These licensed standards allow operators to optimise their existing mobile network infrastructure through an upgrade to EC-GSM-IoT for 2G networks and LTE-MTC for LTE networks, while NB-IoT can use both 2G and 4G spectrum. Backed by 36 global mobile operators, device makers and chipset, module and infrastructure companies, the GSMA Mobile IoT initiative is working to accelerate the development of LPWA solutions and is supporting multiple global pilots with full commercial solutions expected in market later this year.
LPWA at Mobile World Congress Shanghai
There will a number of demonstrations of LPWA technology at the GSMA Innovation City at Mobile World Congress Shanghai, located in Hall N3 (Stands A38 and E37) at the Shanghai New International Expo Centre. Visitors will be able to experience how LPWA networks in licenced spectrum are connecting up everything from pets to street lighting. It will be open during Mobile World Congress Shanghai exhibition hours from Wednesday, 29 June through Friday, 1 July. For more information, visit www.mwcshanghai.com/innovation-city/. The GSMA will also host an IoT Summit on Thursday, 30 June at The Kerry Hotel, Shanghai where delegates will hear from leading industry experts on the latest on Mobile IoT industry applications and technologies. For more information or to register, please visit www.gsma.com/connectedliving/events/.
Get Involved at Mobile World Congress Shanghai 2016
For more information on the 2016 Mobile World Congress Shanghai, including how to attend, exhibit, partner or sponsor, visit www.mwcshanghai.com. Follow developments and updates on Mobile World Congress Shanghai through our social media channels – follow us on Twitter at @GSMA and use #MWCS16, get regular updates through our LinkedIn Showcase Page at www.linkedin.com/company/mobile-world-congress-shanghai, and follow us on Facebook at www.facebook.com/mwcshanghai. In China, you can follow us on Sina Weibo http://weibo.com/mwcshanghai or on the GSMA account on WeChat. For additional information on GSMA social channels, visit www.mwcshanghai.com/register-plan/networking/social-media.
To download the GSMA Intelligence report, ‘Mobile operators and digital transformation’ please follow this link.
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with almost 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i